Melphalan and prednisone: An effective combination for the treatment of multiple myeloma

Costa, Giovanni; Engle, Ralph L.; Schilling, Albert; Carbone, Paul P.; Kochwa, Shaul; Nachman, Ralph L.; Glidewell, Oliver

doi:10.1016/0002-9343(73)90116-2

Cited by 129 publications

(27 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our patient hypertension was corrected as a consequence of cortisol normalization. Although the precise antitumor activity of prednisolone for multiple myelomais unknown, previous reports have shownthat the combination therapy with melphalan and prednisolone was more effective in increasing the number of responders (15,16). Before treatment it was conceivable that cortisol normalization might give unfavorable effects for the clinical course of multiple myeloma, so we started o,p'-DDD at a low dose and increased it gradually.…”

Section: Discussionmentioning

confidence: 99%

A case of cushing's disease and multiple myeloma.

et al. 1989

View full text Add to dashboard Cite

A 55-year-old female of Cushing's disease associated with multiple myeloma is reported. The association of the two diseases has not been previously noted. Elevated cortisol level was controlled successfully by low doses of adrenocorticolytic agent, o,p'-DDD. However, the exacerbation of multiple myelomawas found to accompanythe serum cortisol normalization. Previous reports have shown the good efficacy of combination therapy with melphalan and prednisolone for multiple myeloma. It was suggested that the decrease of endogenous cortisol level might exacerbate the patient's multiple myeloma.

show abstract

Section: Discussionmentioning

confidence: 99%

A case of cushing's disease and multiple myeloma.

et al. 1989

View full text Add to dashboard Cite

show abstract

“…The CL* and Bence Jones protein were tested at equivalent protein concentration (1 mg/ml) for Inv(3) activity. The Inv(3) activity of the whole protein exceeded that expressed by the CL* by 32- (26)(27)(28)(29).…”

Section: Resultsmentioning

confidence: 91%

Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.

Solomon¹,

McLaughlin

Capra

1975

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino-terminal, variant half (VL) Biosynthetic studies were performed with plasma cells derived from the bone marrow of this patient at a time when both the CL* and the Bence Jones protein were being excreted; both proteins were identified in extracellular culture fluid by immunochemical techniques. Whether the CL* is of synthetic or catabolic origin is presently not known; however, the detection of the CL* and the absence of any detectable protein related to the VL in the extracellular culture fluid might imply a synthetic origin of the CL* and suggest a corticosteroidinduced alteration in light chain synthesis.

show abstract

“…In the majority of the cases only a single agent was administered indefinitely until side effects such as anorexia, nausea, paresthesia in limbs, leukopenia, hepatic disturbance, appeared. When one agent was considered as ineffective after administration for 1-3 months from the points of responding criteria generally employed (Alexanian et al 1968;Costa et al 1973), it was switched to another agent. Corticosteroids were administered supplementarily when the above chemotherapeutic agents used seem to have less effect than expected or when they have to be stopped because of side effects.…”

Section: Methodsmentioning

confidence: 99%

“…At present the above view seems to require some correction because of appearance of patients who can survive under fairly good conditions with prolonged survival (Costa et al 1973). …”

mentioning

confidence: 99%